September 29, 2025 8:31pm
For gross proceeds of $345 M
QURE closed up +$5.09 or +9.37% to $59.40 with an aftermarket pricing of -$1.25 or -2.10% to $58.15
QURE had soared by 291% week-on-week to climb to a new all-time high based on astronomical performance of its delivered gene therapy treatment AMT-130 for Huntington’s disease.
The Bottom Line:
In Friday’s session, QURE) soared to its highest 52-week price of $55.11 before trimming gains to end the day just up by 3.15 percent at $54.31 apiece; following an announcement on the same day that its potential treatment slowed progression of Huntington’s disease by 75% after 36 months.
The FDA had granted AMT-130 Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations.
The offering included 947,368 ordinary shares issued pursuant to the exercise in full by the underwriters of their option to purchase additional ordinary shares in the offering; and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase 526,316 of its ordinary shares at the public
Leerink Partners, Stifel, Guggenheim Securities and Van Lanschot Kempen acted as bookrunning managers for the offering. H.C. Wainwright & Co. acted as lead manager for the offering.
